Lilly Inks Two Asia Partnerships with $4.3B Potential, Continues Acquisition Spree
LLY sits 73% above its 52-week low of $623.78 on light trading volume (0.4× avg).
Summary
Eli Lilly announced two new strategic licensing deals today: a collaboration with Haisco Pharmaceutical Group with up to $2.97 billion in potential milestones, and a global licensing deal with Hanmi Pharmaceutical for Sonefpeglutide with up to $1.185 billion in potential milestones. These partnerships, totaling over $4.3 billion in potential value, expand Lilly's metabolic and autoimmune pipeline. This follows three infectious disease acquisitions announced last week with combined potential values exceeding $3.8 billion, highlighting Lilly's aggressive strategy to expand its pipeline across high-need areas.
At the time of this announcement, LLY was trading at $1,077.29 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,149.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.